SignatureFD’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-954
| Closed | -$38.4K | – | 3520 |
|
|
2026
Q1 | $38.4K | Sell |
954
-535
| -36% | -$11.5K | ﹤0.01% | 1883 |
|
|
2025
Q4 | $37.4K | Hold |
1,489
| – | – | ﹤0.01% | 1814 |
|
|
2025
Q3 | $33.7K | Buy |
1,489
+291
| +24% | +$6.79K | ﹤0.01% | 1856 |
|
|
2025
Q2 | $20.7K | Buy |
1,198
+805
| +205% | +$14.9K | ﹤0.01% | 2039 |
|
|
2025
Q1 | $8.6K | Sell |
393
-782
| -67% | -$21.6K | ﹤0.01% | 2411 |
|
|
2024
Q4 | $37.5K | Buy |
1,175
+918
| +357% | +$27.6K | ﹤0.01% | 1729 |
|
|
2024
Q3 | $7.41K | Sell |
257
-99
| -28% | -$3.67K | ﹤0.01% | 2456 |
|
|
2024
Q2 | $13.7K | Sell |
356
-731
| -67% | -$33.1K | ﹤0.01% | 2140 |
|
|
2024
Q1 | $63.9K | Buy |
1,087
+416
| +62% | +$26.5K | ﹤0.01% | 1418 |
|
|
2023
Q4 | $40.2K | Buy |
671
+111
| +20% | +$5.63K | ﹤0.01% | 1577 |
|
|
2023
Q3 | $21.3K | Buy |
560
+391
| +231% | +$17.2K | ﹤0.01% | 1822 |
|
|
2023
Q2 | $15.4K | Buy |
169
+60
| +55% | +$5.18K | ﹤0.01% | 2023 |
|
|
2023
Q1 | $7.19K | Buy |
109
+34
| +45% | +$1.96K | ﹤0.01% | 2359 |
|
|
2022
Q4 | $3.88K | Sell |
75
-3
| -4% | -$159 | ﹤0.01% | 2577 |
|
|
2022
Q3 | $5K | Buy |
78
+27
| +53% | +$1.6K | ﹤0.01% | 2410 |
|
|
2022
Q2 | $2K | Sell |
51
-41
| -45% | -$1.87K | ﹤0.01% | 2703 |
|
|
2022
Q1 | $5K | Buy |
+92
| New | +$4.06K | ﹤0.01% | 2457 |
|
|
2021
Q1 | – | Sell |
-23
| Closed | -$1K | – | 2754 |
|
|
2020
Q4 | $1K | Buy |
+23
| New | +$973 | ﹤0.01% | 2378 |
|
Other funds holding APLS
SignatureFD's APLS Position: Q2 2026 in Review
SignatureFD sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 954 shares — an estimated $38.4K sold.
SignatureFD first reported a position in APLS in Q4 2020 and held it in 18 quarters. The position peaked at $63.9K in Q1 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- SignatureFD reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- SignatureFD sold 954 Apellis Pharmaceuticals shares in Q2 2026, an estimated $38.4K.
- SignatureFD first reported a position in Apellis Pharmaceuticals in Q4 2020 and held it in 18 quarters.
- SignatureFD's Apellis Pharmaceuticals position peaked at $63.9K in Q1 2024.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.